# High-Potency Cannabis: America’s New Pastime and Psychiatry’s Next Challenge > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/high-potency-thc-products-psychiatry-challenges/ > **Published:** 2026-04-16T21:04:16-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:20:19-04:00 > **Clinical Summary:** Explore the clinical challenges of high-potency THC products in psychiatry, including dosing and harm reduction strategies for safer use. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Mental HealthThcDosingPsychiatryHarm Reduction Why This Matters High-potency THC products now dominate the US cannabis market, with concentrates exceeding 80% THC compared to traditional flower at 15-25%. This shift fundamentally changes the risk-benefit profile for both medical and recreational users, requiring updated clinical assessment and harm reduction strategies. Clinical Summary The article highlights the dramatic increase in THC potency across cannabis products, particularly concentrates and vaping products. Higher potency products create dose-response challenges for patients and increase risk of adverse psychiatric effects including anxiety, psychosis, and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). The piece emphasizes that traditional [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) may not apply to today’s high-potency market. Clinical implications include need for updated dosing guidance and enhanced screening for problematic use patterns. Dr. Caplan’s Take “We’re essentially dealing with a different drug than what most research studied. I counsel patients that today’s concentrates require the same caution we’d use with any high-potency medication — start low, go slow, and respect the pharmacology.” Clinical Perspective 🧠 Clinicians should specifically ask about product type and potency when taking cannabis histories. Patients using concentrates need different dosing frameworks than flower users. Consider enhanced monitoring for psychiatric symptoms in patients using high-potency products, particularly those with personal or family history of mood or psychotic disorders. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20High-Potency%20Cannabis%3A%20America%27s%20New%20Pastime%20and%20Psychiatry%27s%20Next%20Challenge%20%40drcaplan&url=https%3A//www.psychiatrictimes.com/view/high-potency-cannabis-americas-new-pastime-and-psychiatrys-next-challenge)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.psychiatrictimes.com/view/high-potency-cannabis-americas-new-pastime-and-psychiatrys-next-challenge)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20High-Potency%20Cannabis%3A%20America%27s%20New%20Pastime%20and%20Psychiatry%27s%20Next%20Challenge%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.psychiatrictimes.com/view/high-potency-cannabis-americas-new-pastime-and-psychiatrys-next-challenge)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.psychiatrictimes.com/view/high-potency-cannabis-americas-new-pastime-and-psychiatrys-next-challenge](https://www.psychiatrictimes.com/view/high-potency-cannabis-americas-new-pastime-and-psychiatrys-next-challenge) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis research?](#What_is_the_clinical_relevance_rating_of_this_cannabis_research) - [What medical areas does this cannabis research focus on?](#What_medical_areas_does_this_cannabis_research_focus_on) - [What specific cannabis compound is being studied?](#What_specific_cannabis_compound_is_being_studied) - [Does this research address cannabis dosing guidelines?](#Does_this_research_address_cannabis_dosing_guidelines) - [Why is this cannabis research considered clinically significant?](#Why_is_this_cannabis_research_considered_clinically_significant) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis research? This research has been assigned a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This means the findings represent emerging developments or policy changes that warrant close monitoring by healthcare professionals. #### What medical areas does this cannabis research focus on? The research primarily focuses on mental health and psychiatry applications of cannabis. It examines therapeutic uses in psychiatric treatment settings and mental health patient populations. #### What specific cannabis compound is being studied? The research specifically examines THC (tetrahydrocannabinol), which is the primary psychoactive component of cannabis. THC is being evaluated for its potential therapeutic effects in mental health treatment. #### Does this research address cannabis dosing guidelines? Yes, dosing is identified as a key component of this research. The study likely provides guidance on appropriate THC dosing protocols for psychiatric and mental health applications. #### Why is this cannabis research considered clinically significant? This research is deemed clinically significant because it addresses the intersection of [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) with mental health treatment. The findings could influence clinical practice guidelines and inform evidence-based cannabis prescribing in psychiatric care. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [High-potency cannabis linked to mental health risks, expert warns](https://cedclinic.com/high-potency-cannabis-linked-to-mental-health-risks-expert-warns/) An expert overview of mental health risks associated with high-potency [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and clinical considerations. [Read More](https://cedclinic.com/high-potency-cannabis-linked-to-mental-health-risks-expert-warns/) Study links commercial cannabis markets to increased addiction Research findings on how commercial cannabis markets influence addiction rates and [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/). Explore Study [Does marijuana cause lung cancer? Doctors reveal what the research says](https://cedclinic.com/cannabis-lung-cancer-research/) A detailed review of current evidence regarding marijuana use and lung cancer risk. [Learn More](https://cedclinic.com/cannabis-lung-cancer-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).